Cargando…

Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults

Respiratory viruses cause significant morbidity and mortality in immunocompromised populations such as stem cell transplant and solid organ transplant patients. Few viruses causing respiratory tract infection have an approved therapy, and many of the viruses have no therapeutic options at all. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkinson, Dana, Hinthorn, Daniel, Danziger-Isakov, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089160/
https://www.ncbi.nlm.nih.gov/pubmed/24146257
http://dx.doi.org/10.1007/s11908-013-0370-0
_version_ 1783509673875341312
author Hawkinson, Dana
Hinthorn, Daniel
Danziger-Isakov, Lara
author_facet Hawkinson, Dana
Hinthorn, Daniel
Danziger-Isakov, Lara
author_sort Hawkinson, Dana
collection PubMed
description Respiratory viruses cause significant morbidity and mortality in immunocompromised populations such as stem cell transplant and solid organ transplant patients. Few viruses causing respiratory tract infection have an approved therapy, and many of the viruses have no therapeutic options at all. In this article, we describe novel agents under development for treatment options against several respiratory viruses.
format Online
Article
Text
id pubmed-7089160
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-70891602020-03-23 Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults Hawkinson, Dana Hinthorn, Daniel Danziger-Isakov, Lara Curr Infect Dis Rep Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors) Respiratory viruses cause significant morbidity and mortality in immunocompromised populations such as stem cell transplant and solid organ transplant patients. Few viruses causing respiratory tract infection have an approved therapy, and many of the viruses have no therapeutic options at all. In this article, we describe novel agents under development for treatment options against several respiratory viruses. Springer US 2013-10-22 2013 /pmc/articles/PMC7089160/ /pubmed/24146257 http://dx.doi.org/10.1007/s11908-013-0370-0 Text en © Springer Science+Business Media New York 2013 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)
Hawkinson, Dana
Hinthorn, Daniel
Danziger-Isakov, Lara
Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
title Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
title_full Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
title_fullStr Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
title_full_unstemmed Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
title_short Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
title_sort novel antiviral agents for respiratory viral infection in immunocompromised adults
topic Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089160/
https://www.ncbi.nlm.nih.gov/pubmed/24146257
http://dx.doi.org/10.1007/s11908-013-0370-0
work_keys_str_mv AT hawkinsondana novelantiviralagentsforrespiratoryviralinfectioninimmunocompromisedadults
AT hinthorndaniel novelantiviralagentsforrespiratoryviralinfectioninimmunocompromisedadults
AT danzigerisakovlara novelantiviralagentsforrespiratoryviralinfectioninimmunocompromisedadults